RAB17: A Potential Drug Target for Cancer (G64284)

Target Name: RAB17

NCBI ID: G64284

RAB17

RAB17: A Potential Drug Target for Cancer

RAB17 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the RAS oncogene family, which is a group of proteins that are known to play a role in the development and progression of many types of cancer.

One of the things that makes RAB17 an interesting potential drug target is its role in the regulation of cell signaling pathways. In particular, RAB17 has been shown to be involved in the signaling pathway known as the RAS/MAPK pathway. This pathway is involved in many different processes in the cell, including cell growth, differentiation, and survival.

The RAS/MAPK pathway is a complex system that involves the recruitment of several different proteins, including RAB17. This protein is thought to play a key role in the regulation of the MAPK/ERK signaling pathway, which is involved in the majority of cell signaling pathways.

In many types of cancer, the RAS/MAPK pathway is often aberrantly activated, leading to the development of a variety of signaling pathways that promote the growth and survival of cancer cells. By targeting RAB17, researchers may be able to disrupt these abnormal signaling pathways and inhibit the growth and survival of cancer cells.

Another potential mechanism by which RAB17 may be targeted as a drug is its role in the regulation of the cytoskeleton. The cytoskeleton is the structure that gives cells their shape and helps to maintain their integrity. RAB17 is thought to be involved in the regulation of the cytoskeleton in a variety of ways, including its role in the assembly and disassembly of microtubules.

Microtubules are a type of protein structure that is involved in the regulation of many different cellular processes, including cell division, transport, and the assembly of organelles. RAB17 is thought to play a key role in the regulation of microtubule assembly and disassembly, which may be an important target for drugs that are designed to disrupt these processes.

In addition to its role in the regulation of cell signaling pathways and the cytoskeleton, RAB17 is also thought to be involved in the regulation of many other cellular processes. For example, it has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs.

Overall, RAB17 is a protein that is involved in a wide range of cellular processes that are important for the development and survival of many different types of cancer. As such, it is a promising target for drugs that are designed to disrupt these processes and inhibit the growth and survival of cancer cells. Further research is needed to fully understand the role of RAB17 as a drug target and to develop effective therapies that can target this protein.

Protein Name: RAB17, Member RAS Oncogene Family

Functions: The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. That Rab is involved in transcytosis, the directed movement of endocytosed material through the cell and its exocytosis from the plasma membrane at the opposite side. Mainly observed in epithelial cells, transcytosis mediates for instance, the transcellular transport of immunoglobulins from the basolateral surface to the apical surface. Most probably controls membrane trafficking through apical recycling endosomes in a post-endocytic step of transcytosis. Required for melanosome transport and release from melanocytes, it also regulates dendrite and dendritic spine development (By similarity). May also play a role in cell migration

The "RAB17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets